Market News

Deutsche Bank Reconfirms a “Buy” Rating on IMI PLC (LON:IMI) and GBX 1475.00 Target; Allscripts Healthcare Solutions (MDRX) Sentiment Is 1.16

Deutsche Bank have a GBX 1475.00 price target on the stock. The price target indicates a potential upside of 16.14% from IMI PLC (LON:IMI)‘s last close price. This rating was disclosed to clients in an analyst report on 15 December.

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. The company has market cap of $2.56 billion. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. It currently has negative earnings. The companyÂ’s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services.

The stock increased 1.19% or GBX 15 during the last trading session, reaching GBX 1271. About 77,887 shares traded. IMI plc (LON:IMI) has 0.00% since December 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 0.56 in 2017 Q2. Its up 0.11, from 0.45 in 2017Q1. It improved, as 3 investors sold IMI plc shares while 8 reduced holdings. 3 funds opened positions while 2 raised stakes. 18.81 million shares or 2.54% less from 19.29 million shares in 2017Q1 were reported. Bridgeway Inc invested 0% of its portfolio in IMI plc (LON:IMI). Morgan Stanley holds 0% in IMI plc (LON:IMI) or 211 shares. Moreover, Blackrock has 0% invested in IMI plc (LON:IMI). Rbf Limited Liability Co has 43,071 shares for 0.01% of their portfolio. Guggenheim Ltd Liability has invested 0% of its portfolio in IMI plc (LON:IMI). Raging Capital Mgmt Lc accumulated 14.73M shares or 2.58% of the stock. Price T Rowe Assoc Inc Md owns 637,744 shares for 0% of their portfolio. Northern holds 0% or 35,926 shares. Panagora Asset Mgmt invested in 0% or 48,786 shares. Symmetry Peak Mngmt Lc holds 0.11% in IMI plc (LON:IMI) or 1.02M shares. Thompson Siegel & Walmsley Ltd Com invested in 0% or 2,400 shares. Spark Investment Mngmt Ltd Liability Company reported 0.01% in IMI plc (LON:IMI). Aspiriant owns 0.01% invested in IMI plc (LON:IMI) for 67,246 shares. Tower Research Limited Liability Company (Trc) reported 13,648 shares. Creative Planning accumulated 33,000 shares or 0% of the stock.

Among 23 analysts covering IMI PLC (LON:IMI), 8 have Buy rating, 2 Sell and 13 Hold. Therefore 35% are positive. IMI PLC has GBX 1500 highest and GBX 700 lowest target. GBX 1193.10’s average target is -6.13% below currents GBX 1271 stock price. IMI PLC had 187 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Monday, February 29 by Barclays Capital. The firm has “Hold” rating by Societe Generale given on Monday, February 29. The firm has “Buy” rating by AlphaValue given on Thursday, July 23. The company was maintained on Wednesday, April 20 by Jefferies. UBS maintained the stock with “Buy” rating in Tuesday, October 6 report. RBC Capital Markets maintained IMI plc (LON:IMI) on Tuesday, October 13 with “Sector Perform” rating. The firm has “Neutral” rating by JP Morgan given on Friday, November 13. The firm has “Neutral” rating given on Thursday, January 12 by Goldman Sachs. The company was maintained on Wednesday, September 30 by JP Morgan. The firm has “Buy” rating by Nomura given on Friday, November 20.

IMI plc designs, manufactures, and services engineered products that control the precise movement of fluids worldwide. The company has market cap of 3.42 billion GBP. The companyÂ’s IMI Critical Engineering division provides critical flow control solutions for vital energy and process industries. It has a 22.86 P/E ratio. This division offers anti-surge valve and actuator systems to liquefied natural gas compression facilities; integrated flow control systems for critical applications in fluid catalytic cracking; valves into the ethylene and polypropylene production processes, as well as delayed coking; and turbine by-pass valves for critical applications in conventional and nuclear power plants.

Since January 1, 0001, it had 0 buys, and 3 selling transactions for $473,840 activity.

Blue Harbour Group L.P. holds 4.58% of its portfolio in Allscripts Healthcare Solutions, Inc. for 9.31 million shares. Glenhill Advisors Llc owns 5.51 million shares or 4.43% of their US portfolio. Moreover, Adirondack Research & Management Inc. has 2.85% invested in the company for 574,033 shares. The New York-based Paradigm Capital Management Inc Ny has invested 2.25% in the stock. S&T Bank Pa, a Pennsylvania-based fund reported 705,807 shares.

The stock decreased 1.77% or $0.255 during the last trading session, reaching $14.155. About 2.48 million shares traded or 19.14% up from the average. Allscripts Healthcare Solutions, Inc. (MDRX) has declined 8.32% since December 15, 2016 and is downtrending. It has underperformed by 25.02% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *